A patient presents with blurry vision for the past 6 months, decreased near vision in the left eye, and unilateral headaches. What should be in the list of differential diagnoses to ensure adequate management? Read this case report to find out more.
When there is suspicion for neuroleptic malignant syndrome, prompt medical therapy and discontinuation of the offending agent are crucial. This report presents an atypical case of this potentially fatal adverse drug reaction.
Here, read 5 case reports of patients with preexisting psychotic disorders seen on the inpatient psychiatry unit of an inner-city community hospital who decompensated for various reasons relating to the COVID-19 pandemic.
OCD, when it becomes chronic, rarely can manifest with secondary physical conditions. Here, the authors report the case of a young man who developed hemorrhoids and life-threatening anal bleeding as a result of OCD.
Delirious mania is a potentially life-threatening but underrecognized neuropsychiatric syndrome. Here, read about a patient whose symptoms were consistent with nonmalignant delirious mania and were successfully treated with lorazepam and carbamazepine.
Bainbridge-Ropers syndrome is a neurodevelopmental genetic disorder associated with mutations in the additional sex combs–like ASXL3 gene on chromosome 18q12.1. This study describes the comorbid psychiatric aspects of this disorder.
Do younger adult patients with hypertensive intracerebral hemorrhage have higher prevalence of comorbidities such as diabetes and worse clinical outcomes in comparison to older patients with this condition? Read on to find out more.
A wide range of psychological outcomes have been observed during the COVID-19 outbreak. Patients often experience the fear of getting sick or dying and feel helpless or stereotyped by others. Read this case report to find out more.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”